FdaApplication
NDA 210598
Identifiers
- fda_app_no: NDA210598
Properties
| Property | Value |
|---|---|
| applicant_name | MYLAN IRELAND LTD |
| application_type | NDA |
| approval_date | 2018-11-09 |
Revenue by product
YUPELRI
| Period | Revenue |
|---|---|
| Q2 2026 | $70.7M |
| Q1 2026 | $62.5M |
| Q4 2025 | $70.6M |
| Q3 2025 | $71.4M |
| Q2 2025 | $66.6M |
| Q1 2025 | $58.3M |
| Q4 2024 | $66.6M |
| Q3 2024 | $62.2M |
| Q2 2024 | $54.5M |
| Q1 2024 | $55.2M |
| Q4 2023 | $60.5M |
| Q3 2023 | $58.3M |
| Q2 2023 | $55.0M |
| Q1 2023 | $47.0M |
| Q4 2022 | $56.0M |
| Q3 2022 | $53.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| YUPELRI | REVEFENACIN | 175MCG/3ML | SOLUTION;INHALATION |
1 product